OKYO Pharma (NASDAQ:OKYO) Given "Buy" Rating at HC Wainwright

Key Points

• HC Wainwright has reaffirmed a "Buy" rating for OKYO Pharma (NASDAQ: OKYO) with a target price of $7.00, suggesting a potential upside of 211.11% from its previous close.
• The stock has recently seen a 13.6% increase, with a one-year low of $0.90 and a high of $3.35.
• OKYO Pharma, a clinical-stage biopharmaceutical company, is developing therapies for inflammatory eye diseases, with its lead product candidate, OK-101, in Phase II clinical trials for dry eye disease.

OKYO Pharma (NASDAQ:OKYO - Get Free Report)'s stock had its "buy" rating reaffirmed by investment analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They presently have a $7.00 target price on the stock. HC Wainwright's target price indicates a potential upside of 211.11% from the company's previous close.

Several other equities research analysts also recently issued reports on OKYO. Zacks Research upgraded OKYO Pharma to a "hold" rating in a research report on Tuesday, September 16th. Wall Street Zen upgraded OKYO Pharma to a "hold" rating in a research report on Saturday, August 9th. One research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $7.00.

OKYO Pharma Trading Up 13.6%

OKYO Pharma stock opened at $2.25 on Tuesday. OKYO Pharma has a 12 month low of $0.90 and a 12 month high of $3.35. The business's 50 day simple moving average is $2.55 and its 200 day simple moving average is $2.03.

Institutional Investors Weigh In On OKYO Pharma

A number of hedge funds have recently added to or reduced their stakes in the stock. Wealth Enhancement Advisory Services LLC bought a new stake in shares of OKYO Pharma during the 2nd quarter valued at $28,000. FNY Investment Advisers LLC bought a new stake in shares of OKYO Pharma during the 1st quarter valued at $25,000. Finally, Dauntless Investment Group LLC bought a new stake in shares of OKYO Pharma during the 1st quarter valued at $2,526,000. 2.97% of the stock is currently owned by hedge funds and other institutional investors.

About OKYO Pharma

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.